Determination of piperazine derivatives in "legal highs";Oznaczanie pochodnych piperazyny w produktach typu "dopalacze"

Problems of Forensic Sciences

Volumn 81, Issue , 2010, Pages 101-113

  Byrska, Bogumiła ^a   Zuba, Dariusz ^a   Stanaszek, Roman ^a  

^a INSTITUTE OF FORENSIC RESEARCH   (Poland)

Author keywords

"Legal highs"; GC MS; HPLC DAD; Piperazine derivatives

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (2 METHOXY PHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; 1 METHYL 3 PHENYLPIPERAZINE; N (3 METHYLBENZYL)PIPERAZINE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

EID: 77957949654     PISSN: 12307483     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bauman M., Clark R., Budzynski A. [et al.], N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4- methylenodioxymethamphetamine (MDMA, or "Ecstasy"), Neuropsychopharmacology 2005, 30, 550-560.
2. De Boer D., Bosman I.J. [et al.], Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market, Forensic Science International 2001, 121, 47-56. (Pubitemid 32758813)
3. Elliot S., Smith C., Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP, Journal of Analytical Toxicology 2008, 32, 172-177.
4. Gee P., Richardson S. [et al.], Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand, Journal of the New Zealand Medical Association 2005, 1227-1231.
5. http://talk.hyperreal.info/thread/11282.
6. http://www.emcdda.europa.eu/publications/drug-profiles/bzp.
7. Krawczyk W., Nowe narkotyki syntetyczne, Problemy Kryminalistyki 2007, 257, 5-12.
8. Maurer H. H., Mass Spectra of Select Benzyl- and Phenyl-Piperazine Designer Drugs, Microgram Journal 2004, 2, 22-26.
9. Peters F. T., Schaefer S. et al., Screening for and validated quantification of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry, Journal of Mass Spectrometry 2003, 38, 659-676. (Pubitemid 36818224)
10. Staack R. F., Piperazine drugs of abuse, The Lancet 2007, 369, 9571.
11. Staack R. F, Frischi G., Maurer H. H., New designer drugs 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and its toxicological detection in rat urine, Journal of Mass Spectrometry 2003, 38, 971-981.
12. Staack R. F., Maurer H. H., Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry, Journal of Chromatography B 2003, 798, 333-342.
13. Stanaszek R., Zuba D., 1-(3-chlorophenyl)piperazine (mCPP) - a new designer drug that is still a legal substance, Problems of Forensic Sciences 2006, 66, 220-228. (Pubitemid 46917310)
14. Szukalski B., Pochodne piperazyny, pirolidyny, benzimidazolu i tryptaminy - nowe narkotyki zmodyfikowane, Problemy Kryminalistyki 2005, 249, 9-15.
15. Tsutsumi H., Katagi M. [et al.], Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine, Journal of Chromatography B 2005, 819, 315-322.
16. Wilkström M., Holmgren P., Alhner J., A2 (N-benzylpiperazine) a new drug of abuse in Sweden, Journal of Analytical Toxicology 2004, 28, 67-70.